Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Evaluating Selinexor in Patients With Relapsed/Refractory DLBCL

Oral selinexor demonstrated durable activity and a 28% response rate in patients with previously treated relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according...
WIB_icon

Bispecific Immune Cell Engager AFM13 Plus Pembrolizumab Produces High Responses in Heavily Treated Hodgkin...

In a phase Ib study published in Blood, treatment with AFM13, a CD30/CD16A bispecific tetravalent innate immune cell engager, was safe and produced promising...

First CAR T-Cell Treatment Approved for Mantle Cell Lymphoma

The FDA granted accelerated approval to brexucabtagene autoleucel (formerly KTE-X19), a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with...
WIB_icon

Large Study Identifies Predictors of Inferior Survival in Patients With Burkitt Lymphoma

A retrospective analysis of data from 30 U.S. cancer centers found that adults with newly diagnosed Burkitt lymphoma (BL) have modest survival rates and...

FDA Grants Accelerated Approval to Tafasitamab-cxix for Relapsed/Refractory DLBCL

The FDA has granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell...

Combination of Tafasitamab and Lenalidomide Leads to Durable Responses in Relapsed/Refractory DLBCL

For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic cell transplantation, treatment with a combination of the...

Oral Selinexor Approved for Relapsed/Refractory DLBCL

The FDA has granted accelerated approval to selinexor for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL...
On location

Ibrutinib Improves Response and Survival Rates in CNS Relapse of Mantle Cell Lymphoma

Compared with standard immunochemotherapy, treatment with ibrutinib was associated with higher response rates and survival rates in patients with mantle cell lymphoma (MCL) and...

Examining Toxicities of CAR T-Cell Therapy in Patients With DLBCL

Chimeric antigen receptor (CAR) T-cell therapy has been an important addition to the treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)....

Can Risk-Adapted EPOCH-R Replace Intensive Therapy for Burkitt Lymphoma?

Adults with Burkitt lymphoma are typically treated with dose-intensive combination chemotherapy derived from pediatric leukemia regimens, which the study investigators noted is “acutely toxic...
Advertisement

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title